FdaApplication
BLA 125814
Identifiers
- fda_app_no: BLA125814
Properties
| Property | Value |
|---|---|
| applicant_name | Merck Sharp & Dohme LLC |
| application_type | BLA |
| approval_date | 2024-06-17 |
Revenue by product
CAPVAXIVE
| Period | Revenue |
|---|---|
| Q2 2026 | $184.0M |
| Q1 2026 | $142.0M |
| Q4 2025 | $279.0M |
| Q3 2025 | $244.0M |
| Q2 2025 | $129.0M |
| Q1 2025 | $107.0M |
| Q4 2024 | $50.0M |
| Q3 2024 | $47.0M |
| Q2 2024 | $0.0M |
| Q1 2024 | $0.0M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (1)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| CAPVAXIVE | — | 84UG/.5ML | Injection |
1 product